Demographic and clinicopathologic characteristics of breast cancer patients with history of oral alendronate use.
e11093 Background: Bisphosphonates therapy reduces the risk of skeletally related complications in patients with bone metastases due to malignancy and bisphosphonates are the most common used agents in the treatment of osteoporosis. However, the effect on clinical and pathological properties of breast cancer with using oral alendronate has not been reported. We investigate retrospectively the demographic and clinico-pathological characteristics of patients with oral alendronate users for longer than 1 year, compared to non-users. Methods: Patients with breast cancer diagnosed from 1998 to 2010 in our clinic were retrospectively analyzed. Patient’s demographics including survival data and tumor characteristics were obtained from medical charts. Breast cancer patients who were taking oral alendronate more than 12 months at the time of breast cancer diagnosis were enrolled as an alendronate users (n=44), where the patients matched with the same age who were not taking oral alendronate were included as a control group (n=444). Results: A total of 488 patients were included in this study. Forty-four patients received an oral alendronate treatment more than one year and 444 patients were considered as nonusers. Median age of both alendronate users and nonusers was 57 (33-89). Lower incidence histological grade III, T3-T4 tumor, and node positivity was seen in alendronate users but not statistically significant. A similar trend for lower incidence of triple negative and higher incidence ER (P=0.13), PR (P=0.12) and HER2 positivity (P=0.21) was also seen in alendronate users but not statistically significant. Disease free survival rate was 150±28 months in alendronate users where as 70±24 months in nonusers (P=0.015). Median overall survival rates could not be obtained but higher in alendronate users but not statistically significant (P=0.13). Conclusions: The use of oral alendronate for longer than one year before the diagnosis of breast cancer was associated with better clinico-pathological properties and significantly improved disease free survival in breast cancer patients.